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Abstract 
Background: Advanced biliary tract carcinomas are associated with a poor prognosis, and palliative chemotherapy 
has only modest benefit. This multi‑centre phase II study was conducted to determine the efficacy of capecitabine in 
combination with oxaliplatin in patients with inoperable gall bladder or biliary tract cancer.
Methods: This was a Phase II, non‑randomised, two‑stage Simon design, multi‑centre study. Ethics approval was 
sought and obtained by the North West MREC, and then locally by the West Glasgow Hospitals Research Ethics Com‑
mittee. Eligible patients with inoperable locally advanced or metastatic adenocarcinoma of the gall bladder or biliary 
tract and with adequate performance status, haematologic, renal, and hepatic function were treated with capecit‑
abine (1000 mg/m2 po, twice daily, days 1–14) and oxaliplatin (130 mg/m2 i.v., day 1) every 3 weeks for up to six cycles. 
The primary objective of the study was to determine the objective tumour response rates (complete and partial). The 
secondary objectives included assessment of toxicity, progression‑free survival, and overall survival.
Results: Forty‑three patients were recruited between July 2003 and December 2005. The regimen was well tolerated 
with no grade 3/4 neutropenia or thrombocytopenia. Grade 3/4 sensory neuropathy was observed in six patients. 
Two‑thirds of patients received their chemotherapy without any dose delays. Overall response rate was 23.8 % (95 % 
CI 12.05–39.5 %). Stable disease was observed in a further 13 patients (31 %) and progressive disease observed in 12 
(28.6 %) of patients. The median progression‑free survival was 4.6 months (95 % CI 2.8–6.4 months; Fig. 1) and the 
median overall survival 7.9 months (95 % CI 5.3–10.4 months; Fig. 2).
Conclusion: Capecitabine combined with oxaliplatin has a lower disease control and shorter overall survival than the 
combination of cisplatin with gemcitabine which has subsequently become the standard of care in this disease. How‑
ever, capecitabine in combination with oxaliplatin does have modest activity in this disease, and can be considered as 
an alternative treatment option for patients in whom cisplatin and/or gemcitabine are contra‑indicated.
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Background
Carcinomas of the gall bladder and biliary system are 
relatively rare malignancies accounting for approxi-
mately 4–5  % of all gastrointestinal cancers in Europe 
and the USA. Patients with these tumours often present 
with advanced disease, and so curative surgical options 
are limited and survival rates poor. Numerous cytotoxic 
agents have been evaluated both as single agent therapy 
and combination chemotherapy regimens (reviewed 
in [1]), but response rates in excess of 30  % have been 
difficult to achieve [1]. Nevertheless, chemotherapy 
can result in a significantly improved survival and an 
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Fig. 1 Progression‑free survival
Fig. 2 Overall survival
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improved quality of life compared with best supportive 
care [2].
One of the most extensively studied cytotoxic agents in 
biliary tract cancer is 5-fluorouracil (5-FU), either alone 
or in combination. Response rates of 10–24 % have been 
reported for 5-FU as single agent [3–6], and of 10–40 % 
when used in combination [1], including 40  % with the 
ECF regimen, although most of these studies have been 
in small numbers of patients. In addition, there were no 
significant differences between single agent 5-FU and 
the FAM combination regimen in terms of median time 
to disease progression or median survival in randomised 
trials [7]. At the time of conducting this study, no stand-
ard therapy existed for advanced gall bladder or biliary 
tract cancer, with gemcitabine monotherapy or the com-
bination of cisplatin with 5-FU among the most widely 
used regimens outside of clinical trials. However, the 
response rate for cisplatin in combination with 5-FU is 
only approximately 30–35 %. Consequently, further clini-
cal trials of novel chemotherapy agents are warranted in 
gall bladder and biliary tract cancer.
Capecitabine is an oral fluoropyrimidine pro-drug 
with preferential conversion to 5-FU in tumour tissue 
compared to normal by exploiting the increased intra-
tumoural expression of thymidine phosphorylase [8], and 
which is now extensively used in the treatment of colon 
[9–15], breast [16, 17] and gastric cancers [18]. Oxalipl-
atin is a third-generation cisplatin analogue, with activity 
and toxicity profiles that differ from those of other plati-
num derivatives, including carboplatin and cisplatin [19] 
and with clinical activity, either alone or in combination 
with 5-FU, in advanced colorectal cancer [9, 11–14, 20].
When the combination of capecitabine with oxaliplatin 
was evaluated in the phase I study, [12] a patient with gall 
bladder carcinoma who had progressed through treat-
ment with a combination of 5-FU and leucovorin, had a 
partial response when treated with XELOX. This, taken 
together with the activity of single-agent 5-FU and of 
5-FU in combination with cisplatin in biliary tract cancer, 
led us to explore the activity of a combination of capecit-
abine and oxaliplatin as a first-line therapy regimen 
within a phase II study in biliary tract cancers..
Patients and methods
Study design
This was a Phase II, non-randomised, two-stage Simon 
design, multi-centre study of capecitabine and oxaliplatin 
combination chemotherapy in patients with inoperable 
locally advanced or metastatic adenocarcinoma of the 
gall bladder or biliary tract. The primary objective of the 
study was to determine the objective tumour response 
rates (complete and partial), and secondary objec-
tives included assessment of toxicity, progression-free 
survival, and overall survival. The study was approved by 
the North West MREC (Multi-Centre Research Ethics 
Committee) and then by the local research committees 
and NHS R&D departments of each participating institu-
tion. All patients gave written, informed, consent prior to 
any study related procedure.
Eligibility criteria
Eligible patients were those with histologically or cyto-
logically confirmed adenocarcinoma of the gall bladder 
or biliary tract, with inoperable disease as determined 
by radiological assessment, laparotomy or laparoscopy. 
All patients had measurable disease, as defined by the 
response evaluation criteria in solid tumours criteria 
[RECIST] [21], with ECOG performance status ≤2, were 
at least 18  years of age, and had adequate renal (serum 
creatinine ≤1.5× institution’s upper limit of normal 
[ULN]), hepatic (bilirubin ≤2.5× ULN; transaminases 
≤5× ULN), and haematological (absolute neutrophil 
count [ANC]  ≥  1500/mm3; platelet counts  ≥  100,000/
mm3; haemoglobin ≥ 10 g/dl) function.
Patients were excluded if they had received any prior 
chemotherapy for metastatic disease, if they had received 
any radiotherapy, hormonal or immunotherapy within 
4 weeks prior to study entry, or if they were unlikely to 
tolerate treatment. Other exclusion criteria included 
patients who were pregnant or of child-bearing poten-
tial and unwilling to use an acceptable method of birth 
control, peripheral sensory neuropathy of >grade 1 of any 
aetiology, known hypersensitivity to fluoropyrimidines 
or oxaliplatin, and any evidence of uncontrolled cardiac 
disease or any other serious medical or psychiatric dis-
order that would be a contra-indication for prescribing 
this chemotherapy regimen. Patients were also excluded 
if they will unable to reliably tolerate and comply with 
oral medication or if they had a lack of physical integrity 
of the GI tract leading to a malabsorption syndrome or 
intestinal obstruction that would impair administration 
or absorption of oral therapy.
Treatment administration
Capecitabine was administered in an intermittent sched-
ule (14 days’ treatment; 7 days’ rest period) at a dose of 
1000  mg/m2 twice daily orally in a 21-day treatment 
cycle. The two daily doses of capecitabine were admin-
istered 12 ±  2 h apart, within 30 min after a meal with 
approximately 200 ml of water. The total daily dose was 
“rounded-up” and given in equally divided twice daily 
doses. Patients were provided with a study diary card to 
record drug administration.
Oxaliplatin was administered on day 1 at a dose of 
130  mg/m2 as a 2-hour intravenous infusion, after the 
morning dose of capecitabine, in a 21-day treatment 
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schedule. If patients developed acute, laryngo-pharyn-
geal dysesthesiae, the subsequent doses of oxaliplatin 
were administered as a 6-h infusion.
Treatment was repeated every 21 days for a maximum 
of six courses, but was discontinued prior to this if there 
was evidence of disease progression, intolerable toxicity 
despite dose modification, patient refusal, or investigator 
decision to discontinue study therapy. Patients received 
prophylactic anti-emetic medication prior to the oxali-
platin infusion with intravenous dexamethasone and 
granisetron, followed by oral dexamethasone and dom-
peridone for 3 and 5 days respectively.
Dose delays and dose modifications
Administration of subsequent courses of capecitabine 
and oxaliplatin was delayed for one week if non-haema-
tological toxicity had not resolved to baseline levels or 
to ≤grade 1, or if the neutrophil count was <1.0 × 109/l 
or if the platelets were <75 × 109/l. Chemotherapy could 
be delayed for a maximum of 2 weeks to allow recovery 
from toxicity. If toxicity did not resolve after a delay of 
2 weeks, then treatment was discontinued. Capecitabine 
was interrupted in patients who developed ≥grade 2 
diarrhoea, stomatitis, or hand-foot syndrome, and doses 
of capecitabine omitted for toxicity were not replaced 
or restored. When toxicities had resolved to grade ≤1, 
capecitabine was recommenced with an appropriate dose 
modification as follows: a reduction of the daily dose by 
25  % for first occurrence of grade 3 toxicity or second 
occurrence of grade 2 toxicity; a reduction of the daily 
dose by 50 % for grade 4 toxicity (first occurrence), grade 
3 toxicity (second occurrence), or grade 2 toxicity (third 
occurrence). Capecitabine was discontinued for grade 
4 toxicity (second occurrence), grade 3 toxicity (third 
occurrence), and grade 2 toxicity (fourth occurrence).
Supportive care
Palliative and supportive care was permitted during the 
study, but patients who required radiotherapy during the 
study were considered to have disease progression and 
were withdrawn from the study. Patients were not per-
mitted to receive any other anti-cancer therapy during 
the study (including hormonal agents and immunother-
apy). The use of prophylactic granulocyte colony stimu-
lating factor (G-CSF) was not permitted during the first 
two cycles of drug administration.
Patient assessments
Patient assessments included clinical evaluation, toxic-
ity assessments (NCI CTC version 2.0) and laboratory 
assessments every 3 weeks. Disease status was evaluated 
prior to starting chemotherapy and after three cycles 
of chemotherapy. Patients with stable disease or who 
were responding could receive a maximum of six cycles 
of chemotherapy, following which disease status was 
re-assessed within 4  weeks of the last cycle of chemo-
therapy. Disease assessment was by chest X-ray and CT 
scan of the abdomen, and other radiological assessments 
were performed as appropriate. Response was deter-
mined using RECIST [21]. Overall survival (all causes) 
was determined from the start of chemotherapy to the 
time of death and progression-free survival measured 
from the start of chemotherapy until subsequent disease 
progression.
Statistical analyses
As responses have been observed with 5-FU, with 
capecitabine and with the combination of capecitabine 
with oxaliplatin within the phase 1 study, a Gehan design 
for this phase II study was not appropriate. Therefore 
using a two-stage Simon design, it was calculated that 
recruitment of a total of 43 patients would give 80  % 
power at the 5 % significance level of detecting a response 
rate of ≥40  %, at which point it would be appropri-
ate to consider further studies with this regimen, and a 
response rate of ≤20 %, below which this regimen would 
not be pursued in subsequent studies. Thirteen patients 
would be recruited in the first stage; if three or fewer 
responses were observed during this stage then recruit-
ment would be halted and no further investigation of the 
combination warranted. If 13 or more responses were 
observed by the end of the study the combination would 
merit further development.
Results
Forty-three patients were recruited from six centres 
between July 2003 and December 2005. One patient was 
subsequently excluded from the analysis as they had 
a CVA and not received any treatment within the trial. 
Patient and tumour characteristics are shown in Table 1. 
A total of 158 courses of chemotherapy were admin-
istered in 42 patients (median  =  3). Eleven patients 
(26.2 %) completed all six planned courses of chemother-
apy. All analyses were performed on an intention to treat 
basis.
Toxicity assessments
Haematological toxicity was minimal with no grade 
3/4 neutropenia or thrombocytopenia, and only one 
occurrence of grade 3/4 anaemia. Grade 3/4 biochemi-
cal abnormalities (worst grade per patient, all cycles) 
included elevated alkaline phosphatase (10), bilirubin 
(3), glucose (3), and ALT, urea, and low albumin (all 1 
each). Sensory neuropathy was observed in 37 patients, 
and was grade 3/4 in 6 patients. Other grade 3/4 toxici-
ties included fatigue (6 patients), vomiting (5), nausea (4), 
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diarrhoea (6), abdominal cramps (2), and anorexia (1) 
(maximum grade per patient).
Dose delays and modifications
Twenty-five patients (59.5  %) received chemotherapy 
without any dose delays. A total of 25 cycles of chemo-
therapy were delayed for thrombocytopenia (3 cycles), 
neutropenia (1), and deranged liver function (1 cycle). 
Other reasons for dose delays (21 cycles) included laryn-
geal dysaethesia, diarrhoea, hypokalaemia, chest infec-
tion, spinal cord compression, DVT, a requirement for 
paracentesis, abdominal pain, biliary sepsis, pulmonary 
embolism and elective change of biliary stent.
Dose modification of capecitabine was required for 
toxicity in 21 patients and of oxaliplatin in 6 patients. The 
duration of infusion of oxaliplatin had to be prolonged in 
5 patients for pharyngo- laryngeal dysaesthesia.
Efficacy
With the exception of the patient who suffered a cerebro-
vascular event (CVA) and did not start treatment, all 42 
patients were included in the efficacy analyses (inten-
tion–to–treat). There was one complete response (2.4 %) 
and 9 patients (21.4 %) had a partial response for an over-
all response rate of 23.8 % (95 % CI 12.05–39.5 %). Stable 
disease was observed in a further 13 (31 %) of patients, 
giving a disease control rate of 54.8 % (CR, PR and SD), 
with progressive disease observed in 12 (28.6  %) of 
patients (Table  2). Seven patients (16.7  %) did not have 
formal repeat assessments of disease status to determine 
response. Of these, five patients were withdrawn early 
due to treatment-related toxicities, one patient with-
drew consent following the first cycle of treatment, and 1 
patient died prior to cycle 2.
The median progression-free survival is 4.6  months 
(95  % CI 2.8–6.4  month; Fig.  1) and the median over-
all survival is 7.9  months (95  % CI 5.3–10.4  months; 
Fig. 2).
Discussion
The aim of this study was to determine the objective 
response rate of a combination of capecitabine and oxali-
platin in patients with advanced gall bladder or biliary 
tract cancer. The hypothesis was that a regimen with 
an objective response rate of >40  % would warrant fur-
ther investigation, while a regimen with a response rate 
of <20  % would not be of further interest. Six patients 
discontinued chemotherapy with this regimen prior to 
the first planned disease re-assessment due to toxicity, 
which is higher than the patient withdrawal rate with 
this regimen in other tumour types, although the grade 
3/4 toxicities were comparable to previous reports of this 
regimen in other tumour types. In total, 10 patients did 
not undergo repeat disease assessments for response. Ten 
of 33 patients assessable for response had an objective 
tumour response for an overall response rate of 30.3  %. 
However, the objective response rate, based on an inten-
tion to treat, in this study was 23  %, and so we do not 
recommend further study of this regimen as a first-line 
therapy regimen patients with advanced gall bladder or 
biliary tract cancer.
A similar response rate (21  %; 95  % CI 9–38  %) was 
observed in another study in which two 3-weekly cycles 
of capecitabine (1000 mg/m2 bid, days 1–14) plus oxalipl-
atin (130 mg/m2 i.v., on day1) were followed by XELOX-
RT (radiotherapy [50.4 Gy] combined with capecitabine 
[750–675 mg/m2 bid] every radiotherapy day and oxali-
platin [40–30 mg/m2] once weekly [22]). The maximum 
tolerated doses of oxaliplatin and capecitabine when 
combined with radiotherapy were 30 and 675  mg/m2, 
respectively. Five patients became operable following this 
chemo-radiotherapy regimen, with three R0 resections 
and this corresponded to a two-year survival of 28 %, and 
with an estimated local tumour control rate at 2 years of 
72  %. Objective response rates of between 18 and 41  % 
Table 1 Patient characteristics
Age, median (years) 60.5 (range 37–81)
Gender
 Male 24 (57.1)
 Female 18 (42.9)
ECOG performance status
 0 9 (21.4)
 1 27 (64.3)
 2 6 (14.3)
Primary tumour
 Gallbladder 18
 Bile ducts 22
 Ampulla of vater 2
Metastatic disease at presentation
 Yes 39
 No 3
Table 2 Response assessment









Unevaluable, target lesions not assessed 7 16.7
Total 42 100
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Table 3 Chemotherapy studies in advanced biliary tract cancer
Author (year) Drug Number of patients Response rate (%)
Taal (1993) [32] MMC 30 10
Patt (1996) [33] 5FU 32 34
Interferon alfa‑2b
Patt (2001) [34] Cisplatin Interferon alpha‑2b 41 21
Doxorubicin
5 FU
Penz (2001) [35] Gemcitabine 32 22
Murad (2003) [36] Gemcitabine 26 31
5FU
Kornek (2001) [37] MMC/Capecitabine vs 51 31
MMC/gemcitabine 20
Ueno (2004) [38] S1 19 21
Alberts (2005) [39] Gem 42 9.5
5FU
Leucovorin
Furuse (2006) [40] Uracil‑tegafur 24 12.5
Doxorubicin
Kim (2006) [41] Gemcitabine 29 34.5
Cisplatin
Okusaka (2006) [42] Gemcitabine 40 17.5
Park (2006) [43] Gemcitabine 27 33.3
Cisplatin
Hong (2007) [44] Capecitabine 32 40.6
Cisplatin
Manzione (2007) [23] Gemcitabine 34 41
Oxaliplatin
Furuse (2008) [45] S1 40 35
Kim (2008) [46] S1 51 30
Cisplatin
Oh (2008) [27] S1 15 6.7
Oxaliplatin
Furuse (2009) [47] Uracil‑tegafur 61 6.6
Doxorubicin
Kim (2009) [25] Gemcitabine 40 15
Oxaliplatin
Sasaki (2009) [48] S1 28 34.3
Gemcitabine
Gruenberger (2010) [30] Cetuximab 30 63
Gemcitabine
Oxaliplatin
Gunnlaugsson (2010) [22] Capecitabine 39 21
Oxaliplatin
Kanai (2010) [49] S1 25 30.4
Gemcitabine
Karachaliou (2010) [24] Irinotecan 28 17.9
Oxaliplatin
Chung (2011) [50] Irinotecan 39 20.5
Gemcitabine
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have been reported with most other oxaliplatin–con-
taining regimens [23–27]. Similarly, response rates of 
6.6–40.6 % have been seen with a number of other com-
bination chemotherapy regimens in this disease (Table 3).
A further study [28] without radiotherapy was very 
similar to ours and looked at oxaliplatin (130  mg/m2) 
and capecitabine (1000 mg/m2 bid, days 1–14) 3 weekly 
as firstline treatment in advanced biliary carcinoma. 65 
patients were stratified prospectively into two groups 
based on location of the primary (gallbladder or extra 
hepatic cholangiocarcinoma (GBC/ECC) versus intra-
hepatic mass-forming type cholangiocarcinoma (ICC)). 
The response rates overall were significantly higher in the 
GBC/ECC (27 % OR, 49 % SD) than ICC group (no objec-
tive response, 33 % SD). Median survival was 12.8 months 
(CI 95 % 10–16.8 months) for for GBC or ECC compared 
with 5.2 months in the ICC (CI 95 % 12.7–20.5 months). 
The morphologically distinct presentations appear to dif-
fer in their presentations and response to cytotoxic drugs 
[29]. Our study replicates similar response rates but our 
survival times were shorter (between those of ICC and 
GBC/ECC groups) which may reflect many reasons, such 
as overall health of the included patients; differences in 
such characteristics will be more apparent given the 
small numbers.
A GERCOR study [30] has looked at the combina-
tion of gemcitabine (1000  mg/m2  day 1) and oxaliplatin 
(100  mg/m2  day 2) fortnightly as firstline treatment in 
biliary tract carcinoma and observed (again with small 
numbers—56 total) similar response rates to ours but 
also that the combination was well tolerated in frailer 
patients (it included patients of performance status (PS) 
>2 in one of the two groups). Group A (PS 0–2, bilirubin 
<2.5× ULN) showed OR in 36 % (95 % CI 18.7–52.3 %), 
stable disease 26 %, progressive disease 39 %. Median PFS 
was 5.7 months and OS was 15.7 months. Group B (PS >2 
and/or bilirubin >2.5× ULN) showed OR 22 % (95 % CI 
6.5–37.4 %), stable disease 30 %, progressive disease 48 %. 
PFS was 3.9  months and OS 7.6  months. A two weekly 
regimen would mean slightly more hospital visits when 
compared with oxaliplatin and capecitabine but again 
may provide an alternative regimen to the current gold 
standard.
Following completion of our study, the combination of 
cisplatin (25 mg/m2) followed by gemcitabine (1000 mg/
m2 days 1 and 8) every 3  weeks for eight cycles is now 
established as the standard of care in this disease fol-
lowing a phase III randomised trial in comparison with 
gemcitabine monotherapy. This regimen results in a 
disease control rate of 81.4  %, median progression-free 
survival of 8.0 months, and a median overall survival of 
11.7  months [31]. The results of our study suggest that 
the combination of capecitabine with oxaliplatin has 
lower disease control and shorter overall survival than 
cisplatin in combination with gemcitabine. However, 
the combination of capecitabine and oxaliplatin remains 
a regimen with activity in this disease, and can be con-
sidered as an alternative treatment option for patients in 
whom cisplatin and/or gemcitabine are contra-indicated.
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